Senores Pharmaceuticals Share Price Target 2025: Breakout or Breakdown Ahead?

Senores Pharmaceuticals Ltd. (NSE: SENORES) has emerged as a notable small-cap stock in India’s pharmaceutical space. Currently trading at ₹670.00, it has attracted attention due to strong revenue growth and recent price action. Investors are now watching closely:
Can Senores hit ₹700 or even ₹825 in 2025?

Latest Market Overview (as of July 25, 2025)

• Current Price: ₹670.00

• 52-Week Range: ₹435 – ₹705

• Market Cap: Approx ₹3,000 Crore

• EPS (TTM): ₹12 – ₹13

• P/E Ratio: ~35–48×

• Public Shareholding: ~31%

• FII/DII Holding: Low (around 3%–6%)

Technical Analysis Today

• Resistance Levels: ₹618.85 / ₹625.55 / ₹633.55

• Support Levels: ₹604 / ₹596

• Pivot Level: ₹610.85

• RSI: Neutral to Bullish

• MACD: Near Bullish Crossover

• Volume: Rising, indicating accumulation

Senores Pharmaceuticals Share Price Target 2025

1. Strong Revenue Surge: FY25 revenue up ~64% YoY

2. ANDA Acquisitions: Buying USFDA products like Topiramate

3. Global Expansion: Entry into US, UK, EU, Canada, and emerging markets

4. API Advantage: Cost-effective APIs fueling margin

5. Positive Investor Buzz: Recent Q1 spike (₹690 intraday)

Risks & Challenges to Monitor

• Valuation Concerns: PE and PB ratios are higher than peers

• Q1 Net Profit Fall: 95% drop YoY despite revenue growth

• Liquidity Risk: Low institutional holding, lower float

• Support Level at Risk: Breakdown below ₹604 may trigger sell-off

• Market Sentiment: Volatility in broader pharma index

What Should Investors Do?

Senores Pharmaceuticals is at a crucial breakout point.
If the stock sustains above ₹664 with strong Q2 results,
a rally toward ₹700–₹825 is possible in 2025.

However, a close below ₹604 could trigger weakness,
dragging the stock toward ₹550–₹580 levels.

Recommendation: Watch for breakout volume and earnings consistency before taking new positions.